Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Research & Development (2024 - 2025)

BioNexus Gene Lab's Research & Development history spans 2 years, with the latest figure at $14876.0 for Q3 2025.

  • For Q3 2025, Research & Development rose 42.46% year-over-year to $14876.0; the TTM value through Sep 2025 reached $56968.0, changed N/A, while the annual FY2024 figure was $47511.0, 13.59% down from the prior year.
  • Research & Development for Q3 2025 was $14876.0 at BioNexus Gene Lab, up from $12557.0 in the prior quarter.
  • Across five years, Research & Development topped out at $17396.0 in Q4 2024 and bottomed at $8198.0 in Q2 2024.